SELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes Trial
NCT04972721 · Completed
Last updated 2026-05-28This study is examining the long-term effects of the medication semaglutide in adults with overweight or obesity who previously participated in a related cardiovascular trial.
What this study is testing ClinicalTrials.gov NCT04972721 ↗
Description as written by the study sponsor.
Participants are being asked to participate in SELECT-LIFE study because participants take part in the SELECT trial. SELECT-LIFE study is a survey-based study that will start when the SELECT trial ends. SELECT-LIFE looks at the long-term effects of participants taking part in the SELECT trial including the trial medicine participants have been taking. When the SELECT trial ends, participants will no longer get the medicine participants got in the study, even if participants decide to take part in the SELECT-LIFE study. Participants will not get any specific treatment or medicine as part of the SELECT-LIFE study, and participants will be treated as participants normally would by their own doctor. The SELECT-LIFE study will last for up to 10 years after SELECT trial ends, and participants will be asked to fill in a questionnaire about their health every 6 months.
Treatments tested
- No treatment given Other
The study is non-interventional with no study-specific treatment during the study and the patients will be treated as per Treating Physician's and patient's own discretion.
| Main thing measured | Time to all-cause death |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Conditions studied | Overweight, Obesity |
| GLP-1 drugs | semaglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04972721 ↗